Tel Aviv University
Genetics and biochemistry
Shay is a PhD student in professor Offen's lab of translational neuroscience at the Sackler Faculty of Medicine at Tel Aviv University. She acquired her B.Sc. in Biology at the Institute of Life Sciences at the Hebrew University of Jerusalem. She completed her M.Sc. with honors in Biomedical Sciences with specialization in genomics and stem cell research, under supervision of Dr. Yossi Buganim in the Faculty of Medicine at the Hebrew University of Jerusalem. During her master's degree she founded BioStart- a community designed to connect students to the biotech industry and the world of entrepreneurship in Jerusalem. After finishing her degree, she acquired experience in the biotechnology industry working as a research at Enlivex Pharmaceuticals Ltd., an immunotherapy company based in Jerusalem. For her PhD, Shay chose to focus on understanding the prion-like transmission of protein aggregations via exosomes in neurodegenerative disorders such as Parkinson's disease and developing novel therapeutic strategies to halt these diseases progression.

Presenter of 1 Presentation

PARKINSON’S DISEASE PATIENTS CSF-DERIVED EXTRACELLULAR VESICLES SPREAD PATHOLOGY THROUGH INTRANASAL ROUTES

Session Type
SYMPOSIUM
Date
Sat, 19.03.2022
Session Time
09:10 AM - 11:10 AM
Room
ONSITE: 133-134
Lecture Time
10:55 AM - 11:10 AM

Abstract

Aims

Parkinson’s disease (PD) is characterized by the gradual appearance of intraneuronal inclusions that are primarily composed of misfolded α-synuclein protein, leading to cytotoxicity and neural death. Recent studies suggest that misfolded α-synuclein may spread transcellularly, inducing pathological aggregates in healthy neurons, and is disseminated via secretion of extracellular vesicles (EVs). Prompted by the hypothesis of Braak et al. that the olfactory bulb is one of the primary propagation sites for the initiation of PD, we sought to investigate the role of EVs in the spread of α-synuclein and progression of PD through the olfactory bulb.

Methods

EVs derived from the cerebrospinal fluid of patients diagnosed with PD or with a nonsynucleinopathy neurodegenerative disorder were administered intranasally to healthy mice. Three months later, mice were subjected to behavior tests and histochemical analysis of midbrain structures.

Results

Mice subjected to the intranasal administration of CSF-derived EVs from PD patients exhibited multiple features consistent with the disease such as motor behavior impairments, α-synuclein aggregations in the substantia nigra and dopaminergic neurodegeneration. In addition, we observed several understudied symptoms such as robust α-synuclein aggregations in the red nucleus, canities, impaired autophagy and astrogliosis of unconventional GFAP isoforms.

Conclusions

Collectively, these data indicate that intranasally administered EVs derived from the CSF of patients with PD can propagate α-synuclein aggregation in vivo and trigger PD-like symptoms and pathology in healthy mice. Deciphering the disrupted pathways leading to definitive parkinsonian symptoms alongside the unconventional pathologies can lead to further resolution of the molecular pathology of PD.

Hide